Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Serumelektrolytter og kontrastinduceret nefropati hos patienter med akut iskæmisk apopleksi, der gennemgår endovaskulær behandling

Effekten af serum elektrolytniveauer på risikoen for kontrastinduceret nefropati hos patienter med akut iskæmisk apopleksi, der gennemgår endovaskulær terapi

This study aims to evaluate the relationship between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients with acute ischemic stroke undergoing endovascular therapy (EVT).

Contrast-induced nephropathy remains a significant complication associated with endovascular procedures and is linked to increased morbidity and mortality. While several risk factors have been identified, the role of serum electrolyte imbalances in the development of CI-AKI has not been fully elucidated.

In this retrospective cohort study, patients treated with EVT between 2018 and 2026 will be analyzed. Patients will be classified based on the presence or absence of CI-AKI according to changes in serum creatinine levels. Demographic data, comorbidities, laboratory parameters-including serum electrolytes-and procedural variables will be compared between groups.

The primary objective is to determine whether serum electrolyte levels are associated with the risk of CI-AKI. Secondary objectives include evaluating 90-day mortality and dialysis dependency in patients who develop CI-AKI.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This retrospective cohort study is designed to evaluate the association between serum electrolyte levels and the development of contrast-induced acute kidney injury (CI-AKI) in patients undergoing endovascular therapy (EVT) for acute ischemic stroke.

Endovascular treatment has become a standard of care for acute ischemic stroke; however, the use of iodinated contrast media carries a risk of nephrotoxicity. Contrast-induced acute kidney injury remains a clinically significant complication and is associated with prolonged hospitalization, increased healthcare costs, and higher mortality rates. Although several well-established risk factors for CI-AKI have been identified, including baseline renal dysfunction, diabetes mellitus, and contrast volume, the role of serum electrolyte imbalances has not been clearly defined.

Electrolyte disturbances may influence renal perfusion, tubular function, and systemic hemodynamics, potentially contributing to the pathophysiology of CI-AKI. Therefore, identifying electrolyte-related risk factors may help improve risk stratification and guide preventive strategies in high-risk populations.

In this study, patients who underwent EVT between 2018 and 2026 will be included. Prospectively collected clinical data will be analyzed retrospectively. Patients will be divided into two groups based on the development of CI-AKI, defined according to changes in serum creatinine levels following contrast exposure.

Comparative analyses will be performed between patients with and without CI-AKI to identify potential predictors. Multivariate regression analysis may be used to determine independent risk factors associated with CI-AKI development.

The findings of this study are expected to provide clinically relevant insights into the role of electrolyte balance in the development of CI-AKI and may contribute to improved peri-procedural risk assessment and patient management strategies in acute ischemic stroke populations undergoing endovascular therapy.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

4760

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Outside of the US
      • Diyarbakır, Outside of the US, Tyrkiet (Türkiye), 21070
        • Fatma Acil

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 100 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

N/A

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

This study includes adult patients (≥18 years) with acute ischemic stroke who underwent endovascular therapy at a tertiary referral center between 2018 and 2026. Patients with sufficient clinical and laboratory data, including pre- and post-procedural serum creatinine measurements, will be eligible for inclusion.

The cohort reflects a real-world population of patients undergoing EVT, encompassing a wide range of demographic and clinical characteristics, including common vascular comorbidities. Patients will be stratified according to the development of contrast-induced acute kidney injury (CI-AKI) for comparative analyses.

Beskrivelse

Inclusion Criteria:

  • Adults aged 18 years or older
  • Patients diagnosed with acute ischemic stroke
  • Patients who underwent endovascular therapy for acute ischemic stroke between 2018 and 2026
  • Patients with a baseline NIHSS score of 6 or higher
  • Patients who received iodinated contrast medium during the endovascular procedure
  • Patients managed under general anesthesia
  • Patients with available pre-procedural and post-procedural serum creatinine measurements sufficient to assess contrast-induced acute kidney injury

Exclusion Criteria:

  • Age younger than 18 years
  • Pre-existing acute kidney injury or chronic kidney disease meeting KDIGO stage 1-3 before endovascular therapy
  • APACHE score greater than 25 at the time of the procedure
  • Known allergy or hypersensitivity to iodinated contrast media
  • Exposure to iodinated contrast media within the previous 2 weeks
  • Use of nephrotoxic medications within the previous 2 weeks
  • History of myocardial infarction or previous stroke
  • Use of vasopressor/inotropic agents such as dopamine at the time of the procedure
  • Systemic steroid use at the time of the procedure
  • Incomplete medical records or missing laboratory data required for evaluation of CI-AKI

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
CI-AKI Group

Patients who developed contrast-induced acute kidney injury (CI-AKI) following endovascular therapy for acute ischemic stroke, defined by an increase in serum creatinine levels according to established diagnostic criteria after contrast exposure. These patients were identified based on post-procedural renal function changes and included in the analysis to evaluate clinical, laboratory, and procedural factors associated with CI-AKI development.

No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development.

Non-CI-AKI Group

Patients who underwent endovascular therapy for acute ischemic stroke but did not develop contrast-induced acute kidney injury based on post-procedural serum creatinine measurements.

No experimental or therapeutic intervention was assigned. This observational retrospective cohort study evaluated patients undergoing endovascular therapy for acute ischemic stroke, who were subsequently categorized based on the presence or absence of contrast-induced acute kidney injury (CI-AKI). The study analyzed demographic, clinical, laboratory (including serum electrolyte levels) and procedural variables to identify potential risk factors associated with CI-AKI development.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of contrast-induced acute kidney injury (CI-AKI)
Tidsramme: Within 48-72 hours after contrast exposure

CI-AKI will be identified based on post-procedural serum creatinine changes after contrast exposure according to established diagnostic criteria.

Within 48-72 hours after contrast exposure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
90-day mortality
Tidsramme: Within 90 days after endovascular therapy

All-cause mortality occurring within 90 days after endovascular therapy in patients with and without contrast-induced acute kidney injury (CI-AKI).

Within 90 days after endovascular therapy
Dialysis dependency in patients with CI-AKI
Tidsramme: Within 90 days after endovascular therapy

Requirement for renal replacement therapy (hemodialysis) within 90 days after endovascular therapy in patients who developed contrast-induced acute kidney injury (CI-AKI)

Within 90 days after endovascular therapy
Change in serum creatinine
Tidsramme: Baseline to 48-72 hours after endovascular therapy

Change in serum creatinine levels from baseline to post-procedural measurements following contrast exposure.

Baseline to 48-72 hours after endovascular therapy
Association between serum electrolyte levels and CI-AKI
Tidsramme: Baseline (pre-procedural measurements)

Evaluation of the relationship between baseline serum electrolyte levels (sodium, potassium, chloride, calcium, magnesium, phosphate) and the development of contrast-induced acute kidney injury.

Baseline (pre-procedural measurements)
Length of hospital stay
Tidsramme: Within 90 days after endovascular therapy

Total duration of hospitalization in days, compared between patients with and without CI-AKI.

Within 90 days after endovascular therapy
Inflammatory markers and CI-AKI relationship
Tidsramme: Baseline (pre-procedural measurements)

Association between inflammatory markers (e.g., C-reactive protein, procalcitonin) and the development of CI-AKI.

Baseline (pre-procedural measurements)
Change in estimated glomerular filtration rate (eGFR)
Tidsramme: Baseline to 48-72 hours after endovascular therapy

Change in estimated glomerular filtration rate (eGFR) from baseline to post-procedural measurements following contrast exposure

Baseline to 48-72 hours after endovascular therapy

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. april 2026

Primær færdiggørelse (Faktiske)

10. november 2026

Studieafslutning (Faktiske)

11. november 2026

Datoer for studieregistrering

Først indsendt

2. april 2026

Først indsendt, der opfyldte QC-kriterier

16. april 2026

Først opslået (Faktiske)

22. april 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 27.012.2026-37

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .